Quantcast

Latest multiple sclerosis Stories

2014-04-29 16:31:14

-- UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent -- ROCKVILLE, Md., April 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II...

2014-04-29 12:33:57

Multiple Sclerosis Patient Kristen Marr Shares Her Stem Cell Treatment Results LA JOLLA, Calif., April 29, 2014 /PRNewswire/ -- As a wife and mother of 2 children, Kristen Marr was absolutely devastated when she was diagnosed with Primary Progressive Multiple Sclerosis in 2007. Five years later, the disease had left her significantly debilitated. Kristen had difficulty walking as her balance was completely off, her energy levels were constantly depleted and she was experiencing...

2014-04-28 16:27:09

PHILADELPHIA, April 28, 2014 /PRNewswire-USNewswire/ -- A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease. Not enough evidence was found to show if medical marijuana is helpful in treating motor problems in...

2014-04-25 08:28:05

ROCKLAND, Mass., April 25, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66(th )Annual Meeting, taking place from April 26 - May 3, in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20121220/SF32295LOGO-b Data from 14 study assessments presented by EMD Serono or its affiliate, Merck Serono, the...

2014-04-24 16:29:59

PHILADELPHIA, April 24, 2014 /PRNewswire-USNewswire/ -- A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced disease activity for people with multiple sclerosis (MS). The study is released today and will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. For the study, 231 people with relapsing-remitting MS received either a placebo or one...

2014-04-22 23:15:15

Natural Multiple Sclerosis Treatment System created by Gary M. Levin is a new program that provides people with natural remedies, techniques, tips, and detailed instructions on how to treat their multiple sclerosis. An overview on the website Vinaf.com shows if the program is good for people to use. New York, NY (PRWEB) April 22, 2014 Multiple sclerosis is the deterioration of the myelin sheaths. Multiple sclerosis patients lose muscular control, feeling in nerves, and even suffer...

2014-04-15 23:02:24

Crowdfunding Gets FDA-Approved Stem Cell Trial Off To Fast Start New York, NY (PRWEB) April 15, 2014 The Tisch MS Research Center of New York (Tisch MSRCNY) today announced that they surpassed their campaign goal on Indiegogo.com to raise funds for their FDA-Approved Phase I Clinical Stem Cell Trial. The funding will be directly applied to the study and stem cell research at Tisch MSRCNY. The target of $300K was met and surpassed within the allotted four weeks of the campaign's launch...

2014-04-11 16:21:36

DUBLIN, April 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market Report" [http://www.researchandmarkets.com/research/btp9ds/global_multiple ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at...

2014-04-08 12:25:22

U.S. Payers Are Sensitive to the Risk Profile of Novel Therapies When Making Formulary Decisions, According to Findings from Decision Resources Group BURLINGTON, Mass., April 8, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, for the treatment of primary-progressive multiple sclerosis (PP-MS), surveyed U.S. neurologists would be willing to accept a certain level of risk for a therapy with proven efficacy on disability progression, likely owing to the absence of approved...

2014-04-08 08:32:16

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/2pf8dt/neuroprotection) has announced the addition of a new report "Neuroprotection - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/2pf8dt/neuroprotection ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report describes the role of neuroprotection in acute disorders such as stroke and injuries...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related